Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).
Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Mia C. Weiss(Washington University in St. Louis), Brittany L. Siontis(Mayo Clinic in Arizona), Mark Agulnik(Northwestern University), Matthew Ingham(Columbia University), Shing M. Lee(Columbia University), Gina Z. D’Amato(University of Miami Health System), Lorraine Pelosof(National Cancer Institute), Mary Louise Keohan(Roche (Switzerland)), Mihaela Druta(Moffitt Cancer Center), Biswajit Das(Frederick National Laboratory for Cancer Research), Mahesh Seetharam(Mayo Clinic in Arizona), Melissa Burgess(University of Pittsburgh Medical Center), Anthony P. Conley(The University of Texas MD Anderson Cancer Center), Brian Andrew Van Tine(Washington University in St. Louis), Benjamin Powers(University of Kansas Medical Center), Li Chen(Zhejiang Chinese Medical University), Liner Ge(Columbia University), A. Chalmers(University of Utah), Gary K. Schwartz(Baylor University Medical Center)
Cited by 3
Related Papers
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573